Rallybio News

Rallybio Analyst Ratings

BenzingaApr 19 12:21 ET

Rallybio Analyst Ratings

BenzingaApr 18 13:17 ET

Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment

TipRanksApr 17 19:15 ET

Rallybio Analyst Ratings

BenzingaApr 11 09:59 ET

Wedbush Sticks to Their Buy Rating for Rallybio (RLYB)

TipRanksApr 11 08:15 ET

Analysts Offer Insights on Healthcare Companies: Rallybio (RLYB), Phathom Pharmaceuticals (PHAT) and Amylyx Pharmaceuticals Inc (AMLX)

TipRanksApr 11 06:30 ET

Buy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program Progress

TipRanksApr 10 20:35 ET

Rallybio's RLYB212 Positioned to Transform FNAIT Prophylaxis Market, Analyst Maintains Buy Rating

TipRanksMar 26 13:55 ET

Rallybio's Clinical Advancements and Solid Financials Earn a Buy Rating From Analyst Ritu Baral

TipRanksMar 13 17:35 ET

Rallybio Analyst Ratings

BenzingaMar 13 07:18 ET

Buy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potential

TipRanksMar 13 06:25 ET

Buy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stability

TipRanksMar 12 17:55 ET

Jefferies Cuts Rallybio to Hold, Cites Lack of Near-term Catalysts

Seeking AlphaFeb 7 11:54 ET

Wedbush Adjusts Rallybio's Price Target to $13 From $14, Keeps Outperform Rating

MT NewswiresFeb 7 08:59 ET

Analysts' Top Healthcare Picks: Rallybio (RLYB), Madrigal Pharmaceuticals (MDGL)

TipRanksFeb 7 08:02 ET

Rallybio Analyst Ratings

BenzingaFeb 7 06:25 ET

Rallybio's Strategic Focus and Strengthened Fiscal Position Garner Buy Rating

TipRanksFeb 6 15:45 ET

Rallybio's Drug Pipeline Promises Breakthroughs in FNAIT and GMG Treatments: Kapoor Maintains Buy Rating

TipRanksJan 5 06:30 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rallybio (RLYB), Avanos Medical (AVNS) and Relmada Therapeutics (RLMD)

TipRanksJan 4 13:10 ET

Rallybio Analyst Ratings

BenzingaDec 21, 2023 11:55 ET